Riliprubart (SAR445088) is a humanized monoclonal antibody that acts as an anti-C1s inhibitor in the proximal part of the classical complement system. It selectively targets activated C1s, inhibiting its enzymatic activity on substrates C4 and C2, thereby preventing the formation of the classical pathway C3 convertase, C4b2a [1].